At ART initiation
| | |
Sex, female, n (%)
|
673
|
(67)
|
Age (years), median (IQR)
|
35.0
|
(29.7-41.9)
|
CD4 count (cell/mm3), median (IQR)
|
186
|
(97–258)
|
WHO clinical stage 3 or 4, n (%)
|
136
|
(13)
|
BMI (kg/m2), median (IQR)
|
21.3
|
(19.1-23.9)
|
Patients on specific ART regimen, n (%)
| | |
2NRTIs + nevirapine α
|
562
|
(55.8)
|
2NRTIs + efavirenz β
|
332
|
(32.9)
|
2NRTIs + ritonavir boosted PI*
|
78
|
(7.7)
|
Others**
|
36
|
(3.6)
|
Hemoglobin (g/dl), median (IQR)
|
10.8
|
(9.4-12.1)
|
Patients with prior use of cotrimoxazole†, n (%)
|
709
|
(70)
|
Follow-up on ART
| | |
Cumulative (PY)
|
2076
| |
Median (IQR), in months
|
17.3
|
(5.7-38.0)
|
Death, n (%)
|
47
|
(4.6)
|
Patients lost to follow-up‡, n (%)
|
128
|
(12.7)
|